Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...

Over the years, I’ve had the privilege of working alongside some extraordinary leaders. When I reflect on those who have left the most lasting impact on me, I often describe them as having what I call ...

Delivering reliable, high-quality software at speed requires more than fast coding—it demands a smarter approach to testing. That’s where the Shift-Left methodology comes in. By moving testing ...

France's Early Access Program (EAP) is a critical pathway for patients with severe or rare conditions to swiftly access innovative therapies, having granted over 120,000 patients early access since ...